Therapeuticsmd Inc Quick Ratio (TXMD) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Therapeuticsmd Inc   (NASDAQ: TXMD)

Therapeuticsmd Inc 's Quick Ratio

TXMD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Therapeuticsmd Inc 's Cash & cash equivalent grew by 9.15 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Therapeuticsmd Inc 's Quick Ratio to 1.84, Quick Ratio remained below Therapeuticsmd Inc average.

Within Major Pharmaceutical Preparations industry 295 other companies have achieved higher Quick Ratio than Therapeuticsmd Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1546, from total ranking in the first quarter 2026 at 1952.

Explain Quick Ratio?
How much Cash & cash equivalents TXMD´s has?
What are TXMD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TXMD Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 7.31 % 3.59 % -7.38 % -17.25 % -19.83 %
Y / Y Cash & cash equivalent Change - 46.54 % 47.91 % - -
Quick Ratio MRQ 1.84 1.71 1.56 - -
TXMD's Total Ranking # 1546 # 1952 # # # 2143
Seq. Current Liabilities Change 1.87 % 2.63 % -3.24 % 6.07 % -1.67 %
Seq. Cash & cash equivalent Change 9.15 % 12.51 % - - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 296
Healthcare Sector # 517
Overall Market # 1468


Quick Ratio Statistics
High Average Low
18.98 4.46 0.03
(Mar 31 2016)   (Sep 30 2012)




Financial Statements
Therapeuticsmd Inc 's Current Liabilities $ 5 Millions Visit TXMD's Balance sheet
Therapeuticsmd Inc 's Cash & cash equivalent $ 9 Millions Visit TXMD's Balance sheet
Source of TXMD's Sales Visit TXMD's Sales by Geography


Cumulative Therapeuticsmd Inc 's Quick Ratio

TXMD's Quick Ratio for the trailling 12 Months

TXMD Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -4.39 % -11.04 % -15.98 % -20.22 % -37.73 %
Y / Y Cash & cash equivalent TTM Growth 132.24 % 47.19 % 161.47 % -58.33 % -70.07 %
Quick Ratio TTM 1.28 0.82 0.69 0.55 0.53
Total Ranking TTM # 1487 # 1931 # 2247 # 1705 # 1805
Seq. Current Liabilities TTM Growth 1.77 % 0.89 % -1.95 % -5.02 % -5.31 %
Seq. Cash & cash equivalent TTM Growth 57.79 % 20.21 % 22.44 % 0 % 0 %

Quick ratio ranking by company, industry and sector >> Back to TXMD Financial Strength Comparisons >> Go to Compare TXMD Quick Ratio to its Competitors

On the trailing twelve months basis TXMD Cash & cash equivalent improved by 9.15 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Therapeuticsmd Inc 's Quick Ratio to 1.28, Quick Ratio remained below TXMD average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Therapeuticsmd Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 4004.

Explain Quick Ratio?
How much Cash & cash equivalents TXMD´s has?
What are TXMD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 434
Healthcare Sector # 888
Within the Market # 1546


trailing twelve months Quick Ratio Statistics
High Average Low
13.53 4.13 0.14
(Dec 31 2016)   (Sep 30 2012)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions
Rani Therapeutics Holdings Inc   5.02 $ 53.391  Millions$ 10.638  Millions
Phio Pharmaceuticals Corp  4.99 $ 12.996  Millions$ 2.606  Millions
Immunic Inc   4.96 $ 155.098  Millions$ 31.260  Millions
Silo Pharma Inc  4.90 $ 5.227  Millions$ 1.066  Millions
Atossa Therapeutics Inc   4.81 $ 26.204  Millions$ 5.451  Millions
Calcimedica Inc   4.71 $ 18.600  Millions$ 3.950  Millions
Kala Bio inc   4.70 $ 7.229  Millions$ 1.538  Millions
Septerna Inc   4.69 $ 372.322  Millions$ 79.316  Millions
Viking Therapeutics Inc   4.57 $ 501.663  Millions$ 109.656  Millions
Camp4 Therapeutics Corporation  4.51 $ 86.398  Millions$ 19.142  Millions
Rein Therapeutics Inc   4.49 $ 43.627  Millions$ 9.709  Millions
Quantum Cyber N v   4.46 $ 13.415  Millions$ 3.005  Millions
Maia Biotechnology Inc   4.41 $ 27.596  Millions$ 6.258  Millions
Azitra Inc   4.40 $ 6.728  Millions$ 1.531  Millions
Cypherpunk Technologies Inc   4.39 $ 7.624  Millions$ 1.737  Millions
Rigel Pharmaceuticals Inc  4.35 $ 225.347  Millions$ 51.858  Millions
Biohaven Ltd   4.28 $ 267.866  Millions$ 62.658  Millions
Incannex Healthcare Inc  4.25 $ 67.711  Millions$ 15.940  Millions
Longeveron Inc   4.20 $ 18.104  Millions$ 4.307  Millions
Vistagen Therapeutics Inc   4.15 $ 46.439  Millions$ 11.192  Millions
Gyre Therapeutics Inc   4.12 $ 86.289  Millions$ 20.957  Millions
Seaport Therapeutics Inc   4.11 $ 64.423  Millions$ 15.674  Millions
Prelude Therapeutics Inc  3.99 $ 151.757  Millions$ 38.042  Millions
Alx Oncology Holdings Inc  3.97 $ 22.753  Millions$ 5.731  Millions
Actinium Pharmaceuticals Inc  3.94 $ 36.473  Millions$ 9.260  Millions
Veru Inc   3.88 $ 23.880  Millions$ 6.156  Millions
Gain Therapeutics inc  3.81 $ 13.084  Millions$ 3.434  Millions
Bolt Biotherapeutics Inc   3.79 $ 29.823  Millions$ 7.867  Millions
Acurx Pharmaceuticals inc   3.72 $ 10.656  Millions$ 2.865  Millions

Date modified: 2026-09-12T06:13:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.